NY-based direct-to-consumer health insurance service Oscar raises $140M led by Tiger Global Management, following its last raise of $225M in June
Oscar, the New York-based health insurance upstart at the vanguard of a wave of venture capital healthcare investment made in the wake …
Context & Ripple Effects
Oscar's December raise is the latest step in a funding ladder that has been climbing for years: a $145M round at a $1.5B valuation in 2015, Alphabet-affiliated capital the same year, then a $165M round led by Founders Fund in 2018 at a reported $3.2B valuation. In June 2020 it pulled in another $225M while claiming a $2B revenue base.
What makes this Tiger Global round notable is its timing: within roughly seven weeks, Oscar filed its S-1 reporting 2020 revenue of $1.67B, up from $1.04B in 2019, and went on to price its IPO at $39 per share. This $140M reads as the last private check before the public markets.
First-order effects
- Oscar enters its IPO window with fresh capital and a second 2020 raise on the record, strengthening the growth story presented in the S-1 filing it filed weeks later.
- Tiger Global secures a lead position in one of the most closely watched healthcare IPOs of the cycle, buying in ahead of the $39-per-share pricing that valued Oscar at $9.5B.
Second-order effects
- A late-stage round this size forces rival direct-to-consumer insurers to either match the fundraising pace or cede the 'venture-backed challenger' positioning Oscar has held since its 2015 debut.
- The quick succession of raises — $225M in June, $140M in December — gives underwriters and public investors a demonstrated appetite signal that supported the $1.44B IPO raise three months later.
Third-order effects
- If the pattern holds, mega late-stage rounds become standard on-ramps rather than optional bridges for venture-backed insurers, concentrating listing-ready scale in fewer, better-capitalized DTC health players.
- Health insurance incumbents face a structural shift where their newest competitors arrive at the public markets already carrying billion-dollar revenue bases built on venture subsidy.
The trend: Venture-backed health insurers are compressing the distance between their final private rounds and public listings, with Oscar's rapid-fire 2020 raises serving as the template.